Latest Hotspot

Zai Lab Starts Worldwide Phase 2 Study Testing ZL-1102 for Treating Chronic Plaque Psoriasis Topically

28 May 2024
3 min read

Zai Lab Limited revealed that the initial participant has received the dose in a worldwide Phase 2 clinical study assessing the effectiveness and safety of the company's proprietary anti-IL-17 experimental treatment, ZL-1102, aimed at treating chronic plaque psoriasis.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

ZL-1102 is an innovative human VH antibody fragment (Humabody®) specifically designed to bind to the IL-17 cytokine. Highlighting its distinct mechanism, ZL-1102 is being advanced as a topical therapy for mild-to-moderate chronic plaque psoriasis (CPP), setting it apart from other anti-IL-17 treatments that address moderate-to-severe cases through systemic delivery.

“This research represents a significant achievement in Zai Lab’s journey and showcases the dedication of our internal R&D team to create new therapies aimed at benefiting patients worldwide,” said Josh Smiley, President and Chief Operating Officer at Zai Lab.

“ZL-1102 is the pioneering IL-17-focused topical therapy under development for patients with milder CPP. By being designed for direct application on psoriatic skin plaques, we anticipate it can prevent unnecessary tissue exposure and reduce the systemic toxicity associated with intravenous or subcutaneous treatments,” said Dr. Harald Reinhart, President and Head of Global Development for Neuroscience, Autoimmune, and Infectious Diseases at Zai Lab.

ZL-1102, still under investigation, is a novel human VH antibody fragment targeting the IL-17A cytokine, formulated into a hydrogel for topical use in chronic plaque psoriasis treatment. Owing to its compact size and other distinctive properties of this molecule class, ZL-1102 exhibits enhanced target affinity and tissue penetration relative to full-sized monoclonal antibodies. This topical treatment could offer superior safety and tolerability, bringing the benefits of IL-17-targeted therapies to the broader patient population with less severe CPP.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 28, 2024, there are 57investigational drugs for the IL-17A target, including 79 indications, 95R&D institutions involved, with related clinical trials reaching 677, and as many as 7296 patents.

ZL-1102 indicates that it is a promising drug in the pharmaceutical industry, with a specific focus on addressing immune system diseases and skin conditions. Its progression to Phase 2 on a global scale underscores the potential impact it may have in the field of biomedicine. However, further information about its development in China, as well as additional clinical trial data, would be necessary to fully assess its potential impact and market prospects.

图形用户界面, 文本, 网站

描述已自动生成

2024 ASCO Reveals These Pharmaceutical Research and Development Trends
Feature Updates
3 min read
2024 ASCO Reveals These Pharmaceutical Research and Development Trends
28 May 2024
To facilitate systematic and intuitive searching and research of ASCO conference clinical results, the synapse database has launched a new dedicated section for the 2024 ASCO conference clinical results.
Read →
Dyne Therapeutics Unveils Positive ACHIEVE and DELIVER Study Results for DYNE-101 in DM1 and DYNE-251 in DMD
Latest Hotspot
3 min read
Dyne Therapeutics Unveils Positive ACHIEVE and DELIVER Study Results for DYNE-101 in DM1 and DYNE-251 in DMD
28 May 2024
Dyne Therapeutics Reveals Latest Clinical Results from ACHIEVE Study of DYNE-101 in DM1 and DELIVER Study of DYNE-251 in DMD Highlighting Significant Effects on Key Disease Indicators and Improvements in Several Functional Outcomes.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 28
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 28
28 May 2024
May 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Rapid-Acting Insulin AT278 Proves Superior in Phase I Trial for Overweight Type 2 Diabetics
Latest Hotspot
3 min read
Rapid-Acting Insulin AT278 Proves Superior in Phase I Trial for Overweight Type 2 Diabetics
28 May 2024
AT278 Ultra-Concentrated Rapid-Acting Insulin Shows Superiority in Phase I Trial for Overweight and Obese Type 2 Diabetics.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.